Aktis Oncology, Inc. Common stock (AKTS) is a publicly traded the market company. As of September 9, 2026, AKTS trades at $24.70 with a market cap of $1.50B and a P/E ratio of -12.98. AKTS moved +0.48% today. Year to date, AKTS is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $14.72 to $34.19. Analyst consensus is strong buy with an average price target of $35.80. Rallies surfaces AKTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest AKTS news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $24.70 |
| Market Cap | $1.50B |
| P/E Ratio | -12.98 |
| EPS | $-1.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.19 |
| 52-Week Low | $14.72 |
| Volume | 50.60K |
| Avg Volume | 0 |
| Revenue (TTM) | $27.38M |
| Net Income | $-167.95M |
| Gross Margin | -2.52% |
6 analysts cover AKTS: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.80.